Addex to Present at the Bio-Europe Spring 2024 Conference

Core Insights - Addex Therapeutics is a clinical-stage pharmaceutical company focused on allosteric modulation-based drug discovery and development [2] - The company will present a corporate update at the Bio-Europe Spring 2024 conference in Barcelona, Spain, from March 18-20, 2024 [1] Company Overview - Addex Therapeutics specializes in developing novel orally available small molecule drugs known as allosteric modulators for neurological disorders [2] - The lead drug candidate, ADX71149, is a positive allosteric modulator (PAM) for mGlu2 and is currently in Phase 2 clinical trials for epilepsy [2] - The second clinical program, dipraglurant, is a negative allosteric modulator (NAM) for mGlu5, under evaluation for post-stroke recovery [2] - Indivior PLC has licensed Addex's GABAB PAM program for substance use disorder development [2] - The company is advancing a preclinical pipeline targeting various conditions, including chronic cough, stress-related disorders, schizophrenia, and mild neurocognitive disorders [2] - Addex shares are listed on the SIX Swiss Exchange and NASDAQ Capital Market under the ticker symbol "ADXN" [2]